Breaking: Turing Pharma Reduces Daraprim Price

Tonight Turing Pharmaceuticals announced price cuts to hospitals up to 50% off list price.

From the press release:

Turing Reduces Cost of Daraprim® (pyrimethamine)

Price cuts of up to 50 Percent for Hospitals, Improving Access & Affordability

“We pledge that no patient needing Daraprim will ever be denied access.”

Zug, Switzerland — November 24, 2015 — Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases and conditions, today unveiled significant price cuts for hospitals on Daraprim.

“Combined with our robust patient access programs, this is an important step in our commitment to ensure ready access to Daraprim at the lowest possible out-of-pocket cost for both hospitals and patients.” said Nancy Retzlaff Turing’s Chief Commercial Officer. “We pledge that no patient needing Daraprim will ever be denied access.”

Turing will provide:

Read the entire release here.